Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone versus aripiprazole for acute mania in bipolar disorder
IRCT20231022059813N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of risperidone and aripiprazole in bipolar disorder (BD) and mania (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in increased energy, Change in elevated mood and 9 more. Started Nov 2023; status: completed.
02
Drugs
risperidonearipiprazole
03
Conditions
bipolar disorder (BD)mania
Beyond the preview
Go deeper on IRCT20231022059813N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231022059813N1.